ER 35794
Alternative Names: ER-35794Latest Information Update: 17 Nov 2006
Price :
$50 *
At a glance
- Originator Eisai Co Ltd
- Class Antineoplastics; Retinoids; Small molecules
- Mechanism of Action Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 May 2001 No Development Reported for Cancer in Japan (Unknown route)
- 03 Dec 1997 Preclinical development for Cancer in Japan (Unknown route)